# Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma

> **NCT03341806** · PHASE1 · COMPLETED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 13 (actual)

## Conditions studied

- Glioblastoma
- GBM

## Interventions

- **DRUG:** Avelumab
- **COMBINATION_PRODUCT:** MRI-guided LITT therapy

## Key facts

- **NCT ID:** NCT03341806
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-13
- **Primary completion:** 2021-10-13
- **Final completion:** 2021-10-13
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2022-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03341806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03341806, "Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03341806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*